Sangui Biotech International (Sangui Biotech International) Total Liabilities : $1.10 Mil (As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Total Liabilities?

Sangui Biotech International's Total Liabilities for the quarter that ended in Mar. 2023 was $1.10 Mil.

Sangui Biotech International's quarterly Total Liabilities increased from Sep. 2022 ($0.99 Mil) to Dec. 2022 ($1.07 Mil) and increased from Dec. 2022 ($1.07 Mil) to Mar. 2023 ($1.10 Mil).

Sangui Biotech International's annual Total Liabilities increased from Jun. 2020 ($0.86 Mil) to Jun. 2021 ($1.01 Mil) and increased from Jun. 2021 ($1.01 Mil) to Jun. 2022 ($1.03 Mil).

Sangui Biotech International Total Liabilities Historical Data

The historical data trend for Sangui Biotech International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Total Liabilities Chart

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Total Liabilities

Get a 7-Day Free Trial

0.45

0.67

0.86

1.01

1.03

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Liabilities	Get a 7-Day Free Trial															1.08	1.03	0.99	1.07	1.10

Sangui Biotech International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sangui Biotech International's Total Liabilities for the fiscal year that ended in Jun. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.936	+	(0.09	+	-2.7755575615629E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.03

Total Liabilities	=	Total Assets (A: Jun. 2022 )	-	Total Equity (A: Jun. 2022 )
	=	0.131	-	-0.895
	=	1.03

Sangui Biotech International's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.027	+	(0.072	+	6.9388939039072E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.10

Total Liabilities	=	Total Assets (Q: Mar. 2023 )	-	Total Equity (Q: Mar. 2023 )
	=	0.089	-	-1.01
	=	1.10

Sangui Biotech International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines